Inhibition of cholesterol biosynthesis by fluorinated mevalonate analogues
The conversion of mevalonate to cholesterol in rat liver homogenates (IC50 = 0.01-1.0 mM) is inhibited by 6- (I), 6,6-di- (II), and 6,6,6-trifluoromevalonate (III), as well as 4,4-difluoromevalonate (IV). Addition of compound I, III, or IV to rat liver homogenates results in the accumulation of 5-ph...
Uloženo v:
| Vydáno v: | Biochemistry (Easton) Ročník 26; číslo 15; s. 4717 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
28.07.1987
|
| Témata: | |
| ISSN: | 0006-2960 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The conversion of mevalonate to cholesterol in rat liver homogenates (IC50 = 0.01-1.0 mM) is inhibited by 6- (I), 6,6-di- (II), and 6,6,6-trifluoromevalonate (III), as well as 4,4-difluoromevalonate (IV). Addition of compound I, III, or IV to rat liver homogenates results in the accumulation of 5-phospho- and 5-pyrophosphomevalonate. The conversion of isopentenyl pyrophosphate to cholesterol is not inhibited by the fluorinated analogues. It thus appears likely that the decarboxylation of mevalonate 5-pyrophosphate is inhibited. Rat liver homogenates catalyze the phosphorylation of I and III. The inhibition of the decarboxylation of mevalonate 5-pyrophosphate by I and III was demonstrated directly with partially purified decarboxylase. Compound I is a remarkably effective inhibitor of the decarboxylation (Ki = 10 nM). Similar results were reported by Nave et al. [Nave, J. F., d'Orchymont, H., Ducep, J. B., Piriou F., & Jung, M. J. (1985) Biochem. J. 227, 247]. It is likely that the phosphorylated or pyrophosphorylated forms of all inhibitors tested are responsible for inhibition. We also describe a chemical method for the synthesis of mevalonate 5-pyrophosphate. |
|---|---|
| AbstractList | The conversion of mevalonate to cholesterol in rat liver homogenates (IC50 = 0.01-1.0 mM) is inhibited by 6- (I), 6,6-di- (II), and 6,6,6-trifluoromevalonate (III), as well as 4,4-difluoromevalonate (IV). Addition of compound I, III, or IV to rat liver homogenates results in the accumulation of 5-phospho- and 5-pyrophosphomevalonate. The conversion of isopentenyl pyrophosphate to cholesterol is not inhibited by the fluorinated analogues. It thus appears likely that the decarboxylation of mevalonate 5-pyrophosphate is inhibited. Rat liver homogenates catalyze the phosphorylation of I and III. The inhibition of the decarboxylation of mevalonate 5-pyrophosphate by I and III was demonstrated directly with partially purified decarboxylase. Compound I is a remarkably effective inhibitor of the decarboxylation (Ki = 10 nM). Similar results were reported by Nave et al. [Nave, J. F., d'Orchymont, H., Ducep, J. B., Piriou F., & Jung, M. J. (1985) Biochem. J. 227, 247]. It is likely that the phosphorylated or pyrophosphorylated forms of all inhibitors tested are responsible for inhibition. We also describe a chemical method for the synthesis of mevalonate 5-pyrophosphate.The conversion of mevalonate to cholesterol in rat liver homogenates (IC50 = 0.01-1.0 mM) is inhibited by 6- (I), 6,6-di- (II), and 6,6,6-trifluoromevalonate (III), as well as 4,4-difluoromevalonate (IV). Addition of compound I, III, or IV to rat liver homogenates results in the accumulation of 5-phospho- and 5-pyrophosphomevalonate. The conversion of isopentenyl pyrophosphate to cholesterol is not inhibited by the fluorinated analogues. It thus appears likely that the decarboxylation of mevalonate 5-pyrophosphate is inhibited. Rat liver homogenates catalyze the phosphorylation of I and III. The inhibition of the decarboxylation of mevalonate 5-pyrophosphate by I and III was demonstrated directly with partially purified decarboxylase. Compound I is a remarkably effective inhibitor of the decarboxylation (Ki = 10 nM). Similar results were reported by Nave et al. [Nave, J. F., d'Orchymont, H., Ducep, J. B., Piriou F., & Jung, M. J. (1985) Biochem. J. 227, 247]. It is likely that the phosphorylated or pyrophosphorylated forms of all inhibitors tested are responsible for inhibition. We also describe a chemical method for the synthesis of mevalonate 5-pyrophosphate. The conversion of mevalonate to cholesterol in rat liver homogenates (IC50 = 0.01-1.0 mM) is inhibited by 6- (I), 6,6-di- (II), and 6,6,6-trifluoromevalonate (III), as well as 4,4-difluoromevalonate (IV). Addition of compound I, III, or IV to rat liver homogenates results in the accumulation of 5-phospho- and 5-pyrophosphomevalonate. The conversion of isopentenyl pyrophosphate to cholesterol is not inhibited by the fluorinated analogues. It thus appears likely that the decarboxylation of mevalonate 5-pyrophosphate is inhibited. Rat liver homogenates catalyze the phosphorylation of I and III. The inhibition of the decarboxylation of mevalonate 5-pyrophosphate by I and III was demonstrated directly with partially purified decarboxylase. Compound I is a remarkably effective inhibitor of the decarboxylation (Ki = 10 nM). Similar results were reported by Nave et al. [Nave, J. F., d'Orchymont, H., Ducep, J. B., Piriou F., & Jung, M. J. (1985) Biochem. J. 227, 247]. It is likely that the phosphorylated or pyrophosphorylated forms of all inhibitors tested are responsible for inhibition. We also describe a chemical method for the synthesis of mevalonate 5-pyrophosphate. |
| Author | Reardon, J E Abeles, R H |
| Author_xml | – sequence: 1 givenname: J E surname: Reardon fullname: Reardon, J E organization: Graduate Department of Biochemistry, Brandeis University, Waltham, Massachusetts 02254 – sequence: 2 givenname: R H surname: Abeles fullname: Abeles, R H |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/3663621$$D View this record in MEDLINE/PubMed |
| BookMark | eNotTz1PwzAU9FBU2sLEjOSJLfDsJE4yogpKUSWW7pE_nomRY5c4Qeq_J4hOd6c73enWZBFiQELuGDwy4OxJOYC8biSwekFWACAy3gi4JuuUvmZZQFUsyTIXIhecrcj7PnROudHFQKOluose04hD9FS5mM5h7DC5RNWZWj_FwQU5oqE9_kgf_ziVYWafE6YbcmWlT3h7wQ05vr4ct2_Z4WO33z4fMlkUzZjxUhtphAFTYM3yHLDhymhgWhXcQlk1wupKV7K0XJTaGgMac16Z2VPI-YY8_Neehvg9z45t75JG72XAOKW2ZlAyXsIcvL8EJ9WjaU-D6-Vwbi_f-S8FOlyj |
| CitedBy_id | crossref_primary_10_1016_S0021_9258_18_55223_6 crossref_primary_10_1016_j_tetasy_2007_08_015 crossref_primary_10_1016_S0003_2697_03_00435_4 crossref_primary_10_1074_jbc_M111_242016 crossref_primary_10_1016_S0022_3565_24_36722_9 crossref_primary_10_1074_jbc_271_14_7895 crossref_primary_10_1016_S0021_9258_17_44789_2 crossref_primary_10_1039_NP9900700025 crossref_primary_10_1016_j_bmcl_2007_10_089 crossref_primary_10_1007_BF01144016 crossref_primary_10_1016_S0022_1139_00_85066_6 crossref_primary_10_1016_0040_4039_88_85053_6 crossref_primary_10_1074_jbc_M109_098350 crossref_primary_10_1016_j_bbagen_2006_03_009 crossref_primary_10_1110_ps_04725204 crossref_primary_10_1016_j_abb_2008_08_024 crossref_primary_10_1007_s00894_009_0561_7 crossref_primary_10_1016_j_abb_2014_12_002 crossref_primary_10_1128_JB_01230_13 crossref_primary_10_1016_j_abb_2010_09_028 crossref_primary_10_1111_j_1440_1681_1993_tb01733_x crossref_primary_10_1016_S0021_9258_17_44813_7 crossref_primary_10_1007_s00894_015_2873_0 crossref_primary_10_1016_j_ejmech_2014_11_040 crossref_primary_10_1016_j_jfluchem_2011_09_014 crossref_primary_10_1111_j_1432_1033_1994_tb18759_x |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1021/bi00389a018 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry |
| ExternalDocumentID | 3663621 |
| Genre | Research Support, U.S. Gov't, Non-P.H.S Research Support, U.S. Gov't, P.H.S Comparative Study Journal Article |
| GroupedDBID | --- -DZ -~X .55 .GJ .HR .K2 186 1WB 23N 3O- 53G 55A 5GY 5RE 5VS 6TJ 85S AABXI AAYJJ ABDPE ABHMW ABJNI ABMVS ABOCM ACGFS ACJ ACNCT ACRPL ACS ADNMO AENEX AEYZD AFFNX AGXLV AIDAL ALMA_UNASSIGNED_HOLDINGS ANPPW ANTXH AQSVZ BAANH CGR CS3 CUPRZ CUY CVF D0L DU5 EBS ECM EIF F5P GGK J5H JG~ L7B LG6 MVM NHB NPM OHT P2P RNS ROL TN5 VG9 VQA VXZ W1F WH7 X7M XOL YQJ YXE YYP YZZ ZCA ZE2 ZGI ZXP ~02 ~KM 7X8 ABBLG AETEA AGQPQ |
| ID | FETCH-LOGICAL-a449t-25cdad6d0d4e81330e92bdc01cb42f05796fc7c7a5f265cfdd0ce327df05be22 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 45 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=10_1021_bi00389a018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0006-2960 |
| IngestDate | Fri Sep 05 11:22:25 EDT 2025 Wed Feb 19 02:33:50 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 15 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a449t-25cdad6d0d4e81330e92bdc01cb42f05796fc7c7a5f265cfdd0ce327df05be22 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 3663621 |
| PQID | 81051250 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_81051250 pubmed_primary_3663621 |
| PublicationCentury | 1900 |
| PublicationDate | 1987-07-28 |
| PublicationDateYYYYMMDD | 1987-07-28 |
| PublicationDate_xml | – month: 07 year: 1987 text: 1987-07-28 day: 28 |
| PublicationDecade | 1980 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Biochemistry (Easton) |
| PublicationTitleAlternate | Biochemistry |
| PublicationYear | 1987 |
| SSID | ssj0004074 |
| Score | 1.4595678 |
| Snippet | The conversion of mevalonate to cholesterol in rat liver homogenates (IC50 = 0.01-1.0 mM) is inhibited by 6- (I), 6,6-di- (II), and 6,6,6-trifluoromevalonate... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 4717 |
| SubjectTerms | Animals Carboxy-Lyases - antagonists & inhibitors Carboxy-Lyases - isolation & purification Cholesterol - biosynthesis Hydrocarbons, Fluorinated - pharmacology Kinetics Liver - metabolism Male Mevalonic Acid - analogs & derivatives Phosphorylation Rats Rats, Inbred Strains Structure-Activity Relationship |
| Title | Inhibition of cholesterol biosynthesis by fluorinated mevalonate analogues |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/3663621 https://www.proquest.com/docview/81051250 |
| Volume | 26 |
| WOSCitedRecordID | wos10_1021_bi00389a018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB6qFfTio7VYn3sQb6HpJpsHCCLFooKlhx56C5t9YKBNqmmF_ntnNwl4EQ9ecgmBZLI7883szPcB3AY-Y6nH8A-g73d8jzMnxkjueJJyQ2831IxbsYlwMonm83jagvtmFsa0VTY-0TpqWQhTIx9ECAQwGLsPqw_HaEaZs9VaQGMH2h4CGdPQFc5_cIW7NQcz5swUgXo9nYdBbZBm5kQs5u4w-h1Z2ggzPvrfux3DYY0syWO1FE6gpfIOdB9zzKqXW3JHbK-nLaJ3YH_U6Lx14fUlf89S27lFCk2MO7TsCcWCpFlRbnOEiGVWknRL9GJj-vUQnkqyNDzhpvSuCM-rClB5CrPx02z07NQKCw73_XjtUCYkl4F0pa8izFZdFdNUCncoUp9qO6eqRShCzjQNmNBSukJ5NJR4L1WU9mA3L3J1BoS5KjDccTqKjbx6FIce85XwqNaB4izqw01jugS_z5xK8FwVmzJpjNeHXmX9ZFXxbCQeoqGADs__fPQCDkztxJRcaXQJbY07V13BnvhaZ-XntV0WeJ1M374BhkbDCw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibition+of+cholesterol+biosynthesis+by+fluorinated+mevalonate+analogues&rft.jtitle=Biochemistry+%28Easton%29&rft.au=Reardon%2C+J+E&rft.au=Abeles%2C+R+H&rft.date=1987-07-28&rft.issn=0006-2960&rft.volume=26&rft.issue=15&rft.spage=4717&rft_id=info:doi/10.1021%2Fbi00389a018&rft_id=info%3Apmid%2F3663621&rft_id=info%3Apmid%2F3663621&rft.externalDocID=3663621 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-2960&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-2960&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-2960&client=summon |